Skip to main content
SpringerLink
Log in

Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with 125I seeds intracavitary irradiation

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

This study aimed at investigating the efficacy of percutaneous transhepatic biliary stenting (PTBS) combined with 125I seeds intracavitary irradiation in the treatment of extrahepatic cholangiocarcinoma (EHC) and to preliminarily explore the prognostic values of inflammation-based scores in these patients.

Methods

A total of 113 clinically/pathologically diagnosed cases of EHC who received PTBS combined with 125I seeds implantation were retrospectively analyzed. The postoperative changes of clinical symptoms and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total serum bilirubin (TBIL), direct bilirubin (DBIL), and albumin (ALB) were observed. Preoperative clinical data were extracted to calculate inflammation-based scores, including systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelets-to-lymphocyte ratio (PLR). Kaplan–Meier survival curves and Cox regression analyses were used to evaluate the prognostic significance of inflammation-based scores.

Results

After operation, clinical symptoms such as jaundice and fever significantly improved in all patients. At 1 month and 3 months postoperatively, serum levels of ALT, AST, ALP, TBIL, and DBIL significantly reduced, and ALB significantly increased, compared with preoperative values. The median survival time of the patients was 12 months and the 1-year survival rate was 56.8%. Univariate analysis revealed that factors related to overall survival were CA19-9, TBIL, ALB, SII, and NLR. Multivariate analysis further identified SII and NLR as independent prognostic models.

Conclusion

The combination of PTBS and 125I seeds intracavitary irradiation is an effective palliative treatment for advanced EHC. Elevated SII and NLR can be used to predict poor survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Cai Y, Cheng N, Ye H, Li F, Song P, Tang W. The current management of cholangiocarcinoma: a comparison of current guidelines. Biosci Trends. 2016;10:92–102.

    Article  PubMed  Google Scholar 

  2. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2017;15:95–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P, et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2017;23:1278–88.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.

    Article  PubMed  Google Scholar 

  5. Indar AA, Lobo DN, Gilliam AD, Gregson R, Davidson I, Whittaker S, et al. Percutaneous biliary metal wall stenting in malignant obstructive jaundice. Eur J Gastroenterol Hepatol. 2003;15:915–9.

    Article  PubMed  Google Scholar 

  6. Wang T, Liu S, Zheng YB, Song XP, Sun BL, Jiang WJ, et al. Clinical study on using 125I seeds articles combined with biliary stent implantation in the treatment of malignant obstructive jaundice. Anticancer Res. 2017;37:4649–53.

    Article  CAS  PubMed  Google Scholar 

  7. Tan Y, Zhu JY, Qiu BA, Xia NX, Wang JH. Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma. Oncol Lett. 2015;10:2537–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.

    Article  CAS  PubMed  Google Scholar 

  9. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125:3347–55.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503.

    Article  PubMed  Google Scholar 

  11. Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Oncotarget. 2016;7:45283–301.

    PubMed  PubMed Central  Google Scholar 

  12. Pang Q, Zhang LQ, Wang RT, Bi JB, Zhang JY, Qu K, et al. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma. World J Gastroenterol. 2015;21:6675–83.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Anderson LL, Hsin MK, Ing-Yuan D. Clinical dosimetry with 125-I. In: George FW, editor. Modern interstitial and intracavitary radiation cancer management. New York: Masson; 1981. p. 9–15.

    Google Scholar 

  14. Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford). 2018;20:379–84.

    Article  Google Scholar 

  15. Lee SH, Park SW. Inflammation and cancer development in pancreatic and biliary tract cancer. Korean J Gastroenterol. 2015;66:325–39.

    Article  PubMed  Google Scholar 

  16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

    Article  CAS  Google Scholar 

  17. Jin H, Pang Q, Liu H, Li Z, Wang Y, Lu Y, et al. Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary metal stents: a retrospective observational study. Medicine (Baltimore). 2017;96:e5895.

    Article  CAS  Google Scholar 

  18. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.

    Article  CAS  PubMed  Google Scholar 

  19. Cidon EU. Resectable cholangiocarcinoma: reviewing the role of adjuvant strategies. Clin Med Insights Oncol. 2016;10:43–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31.

    Article  PubMed  Google Scholar 

  21. Witzigmann H, Lang H, Lauer H. Guidelines for palliative surgery of cholangiocarcinoma. HPB (Oxford). 2008;10:154–60.

    Article  CAS  Google Scholar 

  22. Boulay BR, Birg A. Malignant biliary obstruction: from palliation to treatment. World J Gastrointest Oncol. 2016;8:498–508.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Barkun AN, Adam V, Martel M, AlNaamani K, Moses PL. Partially covered self-expandable metal stents versus polyethylene stents for malignant biliary obstruction: a cost-effectiveness analysis. Can J Gastroenterol Hepatol. 2015;29:377–83.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lee TH, Lee SJ, Moon JH, Park SH. Technical tips and issues of biliary stenting, focusing on malignant hilar obstruction. Minerva Gastroenterol Dietol. 2014;60:135–49.

    CAS  PubMed  Google Scholar 

  25. Mattiucci GC, Autorino R, Tringali A, Perri V, Balducci M, Deodato F, et al. A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer. Brachytherapy. 2015;14:401–4.

    Article  PubMed  Google Scholar 

  26. Popescu CC, Wise J, Sowards K, Meigooni AS, Ibbott GS. Dosimetric characteristics of the Pharma Seed model BT-125-I source. Med Phys. 2000;27:2174–81.

    Article  CAS  PubMed  Google Scholar 

  27. Qiu H, Ji J, Shao Z, Wang J, Ma G, Zhang L, et al. The efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in treatment of advanced lung cancer: a meta-analysis. J Coll Physicians Surg Pak. 2017;27:237–45.

    PubMed  Google Scholar 

  28. Du E, Wang L, Li CY, Zhang CW, Qu YC, Liu RL, et al. Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer. Onco Targets Ther. 2017;10:2561–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kubo M, Satoh T, Ishiyama H, Tabata KI, Tsumura H, Komori S, et al. Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy. Oncol Rep. 2018;39:417–24.

    CAS  PubMed  Google Scholar 

  30. Zhu HD, Guo JH, Zhu GY, He SC, Fang W, Deng G, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. J Hepatol. 2012;56:1104–11.

    Article  CAS  PubMed  Google Scholar 

  31. Shinohara ET, Guo M, Mitra N, Metz JM. Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2010;78:722–8.

    Article  PubMed  Google Scholar 

  32. Nag S, DeHaan M, Scruggs G, Mayr N, Martin EW. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:736–44.

    Article  PubMed  Google Scholar 

  33. Okuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23:636–42.

    Article  PubMed  Google Scholar 

  34. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. https://doi.org/10.1093/jnci/dju124.

    Article  CAS  PubMed  Google Scholar 

  35. Kitano Y, Yamashita YI, Yamamura K, Arima K, Kaida T, Miyata T, et al. Effects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma. Anticancer Res. 2017;37:3229–37.

    CAS  PubMed  Google Scholar 

  36. Suzuki S, Kajiyama H, Shimoda M, Shimazaki J, Koike N, Harada N. Prognostic factors associated with preoperative clinicophysiological outcomes of distal cholangiocarcinoma. Dig Surg. 2017;34:476–82.

    Article  CAS  PubMed  Google Scholar 

  37. Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12:5495–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Oshiro Y, Sasaki R, Fukunaga K, Kondo T, Oda T, Takahashi H, et al. Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2013;20:389–95.

    Article  PubMed  Google Scholar 

  39. Carr BI, Cavallini A, D’Alessandro R, Refolo MG, Lippolis C, Mazzocca A, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14:43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets. 2018;29:569–73.

    Article  CAS  PubMed  Google Scholar 

  41. Plantureux L, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Effects of platelets on cancer progression. Thromb Res. 2018;164(Suppl 1):S40–7.

    Article  CAS  PubMed  Google Scholar 

  42. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128:887–96.

    Article  CAS  PubMed  Google Scholar 

  43. Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013;4:84–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Iwase R, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Futagawa Y, et al. Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Res. 2013;33:3439–44.

    PubMed  Google Scholar 

  45. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta. 1988;948:151–73.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Science and Technology Innovation Fund project of Anhui Province (Grant no. 1501041155).

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Bengbu, 233000, Anhui, China

    X. Hu, Q. Pang, H. Liu, Z. Qian, H. Jin, L. Zhou, Y. Wang, Z. Man, Z. Li & S. Yang

Authors
  1. X. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q. Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z. Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Z. Man
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Z. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Q. Pang or H. Liu.

Ethics declarations

Conflict of interest

All authors declared no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients signed informed consent prior to treatment.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, X., Pang, Q., Liu, H. et al. Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with 125I seeds intracavitary irradiation. Clin Transl Oncol 21, 665–673 (2019). https://doi.org/10.1007/s12094-018-1969-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1969-2

Keywords

Search

Navigation